The effects of intracerebroventricular (ICV) injection of angiotensin II (ANG II) on blood pressure and water intake were examined with the use of ANG II receptor-deficient mice. ICV injection of ANG II increased systolic blood pressure in a dose-dependent manner in wild-type (WT) mice and ANG type 2 AT2 receptor null (knockout) (AT2KO) mice; however, this increase was significantly greater in AT2KO mice than in WT mice. The pressor response to a central injection of ANG II in WT mice was inhibited by ICV preinjection of the selective AT1 receptor blocker valsartan but exaggerated by the AT2 receptor blocker PD-123319. ICV injection of ANG II also increased water intake. It was partly but significantly suppressed both in AT2KO and AT1aKO mice. Water intake in AT2/AT1aKO mice did not respond to ICV injection of ANG II. Both valsartan and PD-123319 partly inhibited water intake in WT mice. These results indicate an antagonistic action between central AT1a and AT2 receptors in the regulation of blood pressure, but they act synergistically in the regulation of water intake induced by ANG II.
ANGIOTENSIN II (ANG II) is a potent vasoactive substance of the renin-angiotensin system (RAS) and plays a major role in hemodynamic regulation, aldosterone release, and cell growth in peripheral tissue (11) . Two distinct ANG II receptor subtypes, type 1 (AT 1 ) and type 2 (AT 2 ), were cloned in 1991 and 1993, respectively (19, 24, 25, 29) . The AT 2 receptor is abundantly and widely expressed in fetal tissues, but its expression declines rapidly after birth (30) and is retained in certain tissues, such as the brain, adrenal gland, uterus, and ovary (36) . Recent studies (17, 34) have demonstrated the existence of all components of RAS, including ANG II receptors, in the central nervous system. The AT 1 receptor, a major subtype of ANG II receptor in adult tissue, is dominantly localized in the regions that control sympathetic activity and vasopressin secretion, such as the ventrolateral medulla, nucleus tractus solitarius, and paraventricular nucleus (3, 18, 27) . In addition, both the AT 1 and AT 2 receptors are expressed in the forebrain and brain stem, which are related to the regulation of blood pressure (17) . Moreover, the AT 2 receptor is also located in the hypothalamus (17, 21) and is predominantly expressed in the ventral part of the brain (12) . These findings suggest that the brain RAS plays an important role in hemodynamic regulation.
It has been reported (6, 7) that the intracerebroventricular (ICV) injection of ANG II increased systemic blood pressure in mice. This increase was significantly suppressed in AT 1 a receptor null (knockout) (AT 1 aKO) mice but not in AT 1 bKO mice, suggesting that the AT 1 a receptor plays a major role in the regulation of blood pressure. Because the AT 2 receptor is also present in the brain, this subtype may contribute to blood pressure regulation by the brain RAS. Recent evidence (1, 5, 37) suggests that AT 2 receptor stimulation exerts antagonistic effects against the AT 1 receptor-mediated functions in peripheral tissues. Thus, in the present study, we explored the effect of ICV microinjection of ANG II and the involvement of the central AT 2 receptor in blood pressure regulation in relation to that of the AT 1 receptor with the use of receptor gene KO mice.
MATERIALS AND METHODS
Animals. Adult male wild-type (WT), AT2 receptor null (AT 2KO) (13) AT1aKO (32) , and AT2/AT1aKO mice aged 10-12 wk (25-30 g body wt) were used in this study. AT 2/ AT 1aKO mice were generated by crossing AT2KO and AT 1aKO mice. The animals were housed in a room where lighting was controlled (12 h on and 12 h off), and the temperature was maintained at 25°C. They were given a standard diet (MF, Oriental Yeast) and water ad libitum. The genotype of animals was determined by RT-PCR after DNA was extracted from tail samples. All experiments were approved by the Animal Studies Committee of Ehime University.
Implantation of microcannula into intracerebroventricle and central administration of ANG II.
While under anesthesia with ketamine (70 mg/kg) and xylazine (4 mg/kg), the mice were stereotaxically implanted with a chronic doublewalled stainless steel cannula in a unilateral cerebral ventricle, as previously reported (31) . The stereotaxic coordinates were 0.4 mm posterior and 1.0 mm lateral to the bregma, according to the method of Franklin and Paxinos (9), and 2.5 mm below the surface of the skull. Animals were allowed 7 days of recovery before the experiments took place. The localization of the cannula was confirmed by preparing brain sections following injection of dye after the experiment.
ANG II was diluted in saline and administered in 0.5 l into the cerebral ventricle. The AT 1 receptor blocker valsartan (donated by Novartis Pharma) and the AT2 receptor blocker PD-123319 (Research Biochemicals International) were diluted with saline and administered in 1.0-l increments into the cerebral ventricle 10 min before ANG II injection. Experiments were started between 9 and 11 AM. Mice were allowed at least 30 min to adapt before ANG II injection to obtain a stable basal level of blood pressure. After ANG II injection with the use of a microsyringe connected to a microinjector, systolic blood pressure was measured in conscious mice for 30 min by the indirect tail-cuff method with a blood pressure monitor (model MK-1030, Muromachi Kikai; Tokyo, Japan) (33) .
To measure the water intake of mice, the animals were kept in metabolic cages (Natsume Seisakusyo; Tokyo, Japan) for 7 days before the experiment. Water intake was measured by weighing the water bottle in the metabolic cage for 30 min before and after ICV injection of ANG II.
Determination of plasma vasopressin concentration. Blood samples were obtained by decaptation 2 min after central injection of ANG II or vehicle and mixed with EDTA (1 mg/ml) and aprotinin (500 KIU/ml). Plasma samples were stored at Ϫ80°C until use. After the plasma was prepared by the C18 Sep column-extraction method (according to the manufacturer's protocol), arginine vasopressin (AVP) was determined with an enzyme immunoassay kit (Peninsula Laboratories).
Statistical analysis. Values are expressed as means Ϯ SE in the text and figures. Data were analyzed by one-way analysis of variance. If a statistically significant effect was found, a Newman-Keuls test was performed to detect the difference between the groups. A value of P Ͻ 0.05 was considered to be statistically significant. Fig. 1 , basal systolic blood pressure was not different between WT and AT 2 KO mice (98.4 Ϯ 0.8 and 101.9 Ϯ 0.9 mmHg, respectively) but was significantly lower in AT 1 aKO and AT 2 /AT 1 aKO mice (79.3 Ϯ 0.9 and 80.1 Ϯ 0.8 mmHg, respectively; P Ͻ 0.05 vs. WT). AT 2 /AT 1 aKO mice did not show any apparent physiological changes, such as body weight gain, and histological features of heart, artery, and brain. ICV injection of ANG II increased systolic blood pressure in WT mice. The pressor response reached a peak ϳ3-5 min after ANG II injection and recovered to the basal level within 20 min (Fig. 1) . The time course of the pressor response in AT 2 KO, AT 1 aKO, and AT 2 / AT 1 aKO mice was not different from that in control mice. The maximum increase in blood pressure induced by central ANG II injection was dose dependent in WT mice between 50 and 200 ng (Fig. 2) . The pressor response after the central injection of ANG II was significantly larger in AT 2 KO mice within the range of 50-200 ng. In contrast, AT 1 aKO mice showed a smaller response of blood pressure after central ANG II injection (Fig. 2) . In these mice, there was no obvious dose dependence of the response, although a high dose of ANG II (200 ng) slightly increased blood pressure. The response in AT 2 /AT 1 aKO mice to a higher dose (200 ng) of ANG II tended to be larger than the response in AT 1 aKO mice (Fig. 2) .
RESULTS

Effect of central ANG II injection on arterial blood pressure. As shown in
In WT mice, the increase in blood pressure induced by central injection of 100 ng ANG II was inhibited by ICV preinjection of the selective AT 1 receptor blocker valsartan in a dose-dependent manner (Fig. 3A) . Nearmaximum inhibition by valsartan was observed at 0.5 Fig. 1 . Change of systolic blood pressure after central injection of angiotensin II (ANG II) in wild-type (WT) mice, ANG type 2 receptor null (knockout) (AT2KO) mice, and ANG type 1a KO (AT1aKO) mice and AT2/AT1a KO mice (AT2/AT1aKO). A microcannula was implanted into the cerebral ventricle and ANG II was injected, as described in MATERIALS AND METHODS. ICV, intracerebroventricular. Values are means Ϯ SE (n ϭ 7-9 mice per group). *P Ͻ 0.05 vs. WT. g (ϳ70%; Fig. 3A ). In contrast, pretreatment of mice with the selective AT 2 receptor blocker PD-123319 enhanced the pressor response induced by central ANG II injection dose dependently in WT mice (Fig. 3A) . The maximum effect was caused by 5 g PD-123319. Central injection of 0.5 g valsartan or 5 g PD-123319 without ANG II did not significantly change systolic blood pressure, whereas blood pressure tended to increase after injection of PD-123319 (Fig. 3B) . In AT 2 KO mice, the pressor response after central injection of ANG II was inhibited ϳ45% by valsartan; however, this inhibition was significantly smaller than that in control ( Fig. 3B ; P Ͻ 0.05). PD-123319 did not significantly affect the blood pressure in AT 2 KO mice.
On the other hand, ICV injection of ANG II (100 ng) did not influence systolic blood pressure in AT 1 aKO mice (Fig. 3B) . In these mice, PD-123319 did not significantly change the blood pressure after central injection of ANG II (Fig. 3B) , suggesting that AT 1 a receptor stimulation is a prerequisite for the AT 2 receptor to exert an antagonistic effect on blood pressure regulation.
Effect of central ANG II injection on water intake. As shown in Fig. 4 , ICV injection of ANG II at a dose of 100 ng increased water intake fivefold in WT mice. This increase was decreased ϳ40% in AT 2 KO mice and ϳ60% in AT 1 aKO mice compared with that in WT mice. In AT 2 /AT 1 aKO mice, a central ANG II injection did not significantly affect water intake. Figure 5 shows that the effect of ANG II on water intake in WT mice was significantly inhibited by valsartan and by PD-123319. In AT 2 KO mice, valsartan, but not PD-123319, significantly inhibited water intake stimulated by a central ANG II injection (Fig. 5) . In AT 1 aKO mice, however, PD-123319 but not valsartan suppressed water intake induced by central ANG II injection ϳ40% (Fig. 5) . The basal level of water intake was not different among WT, AT 2 KO, AT 1 aKO, and AT 2 / AT 1 aKO mice.
Plasma AVP after ICV injection of ANG II. ICV injection of ANG II increased plasma AVP level in WT mice (Fig. 6 ). This increase was significantly larger in AT 2 KO mice but smaller in AT 1 aKO and AT 2 /AT 1 aKO mice than in WT. The basal level of plasma AVP was not different among these groups.
DISCUSSION
In this report, we studied the roles of ANG II receptor subtypes in the brain in the regulation of systemic blood pressure and water intake by using ANG II receptor gene-deficient mice and selective ANG II receptor blockers. Our results using ANG II receptor gene-deficient mice indicated that stimulation of the central AT 1 a receptor by ICV injection of ANG II increased both systolic blood pressure and water intake. Stimulation of the AT 2 receptor, however, antagonized the AT 1 a receptor function and lowered blood pressure. In contrast, AT 2 receptor stimulation increased water intake synergistically with AT 1 a receptor stimulation. The effects of an ANG II receptor blocker on blood pressure and water intake were consistent with the results in ANG II gene-deficient mice. We used the doses of ANG II and ANG II receptor blockers according to those in the previous studies (2, 6, 10, 28) . In our experiments, ICV injection of ANG II showed dose dependency in pressor response up to 200 ng (Fig. 2) . AT 1 and AT 2 receptor blockers also induced the dosedependent action, and 0.5 g valsartan and 5 g PD-123319 showed near-maximal effects, similar to the results in previous studies (2, 10) . These results suggest that the AT 2 receptor in the brain plays an important role in the regulation of peripheral blood pressure and water intake in combination with the AT 1 a receptor.
In the peripheral RAS, most of the physiological actions induced by ANG II are thought to be mediated by the AT 1 a receptor, a major isoform of the AT 1 receptor. The AT 2 receptor counteracts functions mediated by the AT 1 receptor, such as cell proliferation, apoptosis, and aldosterone release (8) . It has been reported (20) that a local RAS is present in the central nervous system, and previous studies (12, 17, 18, 21, 27, 36) demonstrated the existence of both AT 1 a and AT 2 receptors in the central nervous system. These ANG II receptors in the brain seemed to be involved in the pressor response, drinking, and vasopressin release (6, 14, 35) . Li et al. (22) demonstrated that paraventricular AT 1 receptors were critical in salt-sensitive hypertension in mRen-2 transgenic rats. Davisson et al. (6) also reported that the AT 1 a receptor in the brain plays a major role in the control of blood pressure. In our results, AT 1 aKO mice also showed a lower basal level of blood pressure than WT mice. However, basal blood pressure in AT 2 KO mice was not significantly different from that in WT mice. Moreover, basal blood pressure in AT 2 /AT 1 aKO mice was similar to that in AT 1 aKO mice. These results indicate that the central AT 2 receptor is not essential to maintain the basal level of blood pressure. However, the AT 2 receptormediated signal in the brain antagonizes the central AT 1 receptor-mediated action on blood pressure when the brain AT 1 receptor is stimulated. The pressor response to ICV injection of ANG II was greater in AT 2 KO mice than in WT mice. In addition, ICV preinjection of PD-123319 enhanced the pressor response after central injection of ANG II in WT mice, and the inhibitory action of valsartan on the blood pressure increase induced by central ANG II was weaker in AT 2 KO mice than in WT mice. Consistent with these observations, Hein et al. (13) reported that AT 2 KO mice had increased sensitivity to the pressor effect of peripheral injection of ANG II. Nishioka et al. (26) also indicated that AT 2 receptors play a depressor role in sodium-induced pressor response. The effect of central ANG II on peripheral blood pressure may be mediated by the peripheral neuroendocrine system. Previous studies (16, 27) reported that RAS in the brain modulates sympathetic nerve activity through brain AT 1 and AT 2 receptors. Thus it is possible that the AT 2 receptor in the brain induces the antagonistic action against the AT 1 receptor-mediated pressor response by regulating the sympathetic nervous system, which remains to be explored.
In contrast to the regulation of systemic blood pressure, the central AT 2 and AT 1 a receptors seemed to act additively or synergistically to increase water intake. Previous studies demonstrated the importance of the brain AT 1 receptor in the fluid/electrolyte balance. Morris et al. (23) reported that the AT 1 a receptordeficient mice showed a differential response to dehydration. Davisson et al. (6) indicated that the AT 1 b receptor but not the AT 1 a receptor in the brain was responsible for a major portion of drinking motivation. The reason for such a discrepancy has not yet been clarified. However, it may be due to the different markers of drinking in these studies because other studies measured drinking behavior and we measured the volume of water intake. Moreover, the present study indicated that not only the AT 1 but also the AT 2 receptor was involved in the regulation of water intake by the central nervous system. Consistent with our results, Hein et al. (13) observed that AT 2 KO mice had an impaired drinking response to water deprivation. Other reports using receptor antagonists also supported our results. Alova et al. (2) reported that not only AT 1 receptor blocker but also AT 2 receptor antagonist inhibited water intake induced by ICV injection of ANG II in rats. Moreover, Camara et al. (4) indicated that ICV ANG II stimulated both central AT 1 and AT 2 receptors to induce drinking in high-sodium chloride fed rats. These findings indicate that the regulatory mechanism of water intake mediated by central ANG II differs from that of the pressor response and that AT 1 and AT 2 receptors in the brain seemed to act synergistically in the control of drinking. The mechanism of action of the AT 1 and AT 2 receptors on drinking is not yet fully clarified. Previous reports (14, 15, 17) indicated that ANG II in the brain affects vasopressin secretion. Because vasopressin regulates water retention, we measured the change of AVP in plasma after central injection of ANG II. From the results using ANG II receptor-deficient mice and ANG II receptor blockers, it was concluded that the AT 1 receptor in the brain stimulated AVP release, whereas a central AT 2 receptor antagonized such action of the AT 1 receptor, when the AT 1 receptor signal was activated. Stimulation of the central AT 2 receptor alone did not seem to affect plasma AVP level, because the effect of ICV injection of ANG II did not differ between AT 1 aKO and AT 2 /AT 1 aKO mice. Because such a response pattern of AVP in ANG II receptor-deficient mice was different from that of water intake, the regulation of drinking via the central AT 1 and AT 2 receptors may involve not only vasopressin but also other factors.
Although the mechanism of the regulation of hemodynamic changes by the central RAS has not yet been fully clarified, it is of interest that the pressor response and water intake are regulated by AT 1 and AT 2 receptors in a different manner. This may be at least partly caused by the different distribution of AT 1 and AT 2 receptors in the brain, which remains to be clarified. Our results also suggest the possibility that the functional balance of central AT 1 a and AT 2 receptors plays an important role in the mechanism of hypertension.
